Our Platform

VBL is pioneering a new class of drugs called Lecinoxoids to treat immune-inflammatory diseases, including psoriasis, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease and multiple sclerosis. Using its unique drug discovery capabilities, VBL Therapeutics has developed a series of proprietary phospholipid analogs from the Lecinoxoid family that are rationally designed as orally available, disease-modifying agents to address the substantial unmet needs in immune-inflammatory diseases.